DLX4 and inflammatory breast carcinoma: Interestingly, Man et al. [30] demonstrated that protein expression of DLX4 (referred to as BP-1), measured by immunohistochemistry (IHC), is significantly higher, both in intensity and percentage of cells, in IBC cases from the Inflammatory Breast Cancer Registry (IBCR) than in non-IBC cases.